Astrazeneca (AZN) Current Leases (2017 - 2025)

Astrazeneca's Current Leases history runs 8 years deep, the most recent figure standing at $382.0 million for Q4 2025.

• In Q4 2025, Current Leases rose 12.68% year-over-year to $382.0 million; the TTM figure through Dec 2025 stood at $382.0 million (up 12.68% YoY), while the FY2025 annual figure was $382.0 million, up 12.68% from the prior year.
• Current Leases was $382.0 million for Q4 2025 at Astrazeneca, up from $339.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $382.0 million in Q4 2025 to a low of $228.0 million in Q4 2022.
• Historically, Current Leases has averaged $290.6 million across 5 years, with a median of $271.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Current Leases dropped 2.15% in 2022, then climbed 25.09% in 2024.
• A 5-year view of Current Leases shows it stood at $233.0 million in 2021, then decreased by 2.15% to $228.0 million in 2022, then increased by 18.86% to $271.0 million in 2023, then gained by 25.09% to $339.0 million in 2024, then climbed by 12.68% to $382.0 million in 2025.
• The last three Current Leases figures came in at $382.0 million (Q4 2025), $339.0 million (Q4 2024), and $271.0 million (Q4 2023), per Business Quant data.